XKDCT225

· Shenzhen Celconta Life Science Co., Ltd.

Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for XKDCT225, covering 2025-01-17 to 2025-01-17. Get the full timeline:

Most recent: Clinical Trial Update: Treating Claudin18.2-positive Advanced Solid Tumors with XKDCT225(Targeting Claudin18.2-CAR-T) [Phase 1]